Chicago, IL – November 8, 2024 – Today, Zacks Investment Ideas feature highlights AbbVie ABBV, Visa V and Comfort Systems USA ...
Comfort Systems USA, a current Zacks Rank #2 (Buy), offers ... Shares yield 0.7% annually. AbbVie's recent set of results pleased investors, with shares enjoying a bullish move following the ...
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...
Bristol Myers Squibb (BMY) climbed over +10% and was the top percentage gainer on the S&P 500 after rival AbbVie plummeted on news that its ... Roivant Sciences (ROIV), Repligen (RGEN), Rocket Lab USA ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
November 12, 2024. More for You ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback